A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha (Q44034420)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha |
scientific article |
Statements
1 reference
A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha (English)
1 reference
Lissoni P
1 reference
Vaghi M
1 reference
Ardizzoia A
1 reference
Malugani F
1 reference
Fumagalli E
1 reference
Bordin V
1 reference
Fumagalli L
1 reference
Bordoni A
1 reference
Mengo S
1 reference
Gardani GS
1 reference
Tancini G
1 reference
1 March 2002
1 reference